Targeting MEK and PI3K/mTOR in combination had synergistic effects on the relative viability in three AML cell lines (MOLM13, MV4-11, and THP1), and essentially additive effects in two others (KG1 and Kasumi-1) (Supplementary Figure S2). The gene discussed is MTOR; the disease is acute myeloid leukemia.